DE68925935D1 - Antikörper gegen Interleukin-1-beta - Google Patents

Antikörper gegen Interleukin-1-beta

Info

Publication number
DE68925935D1
DE68925935D1 DE68925935T DE68925935T DE68925935D1 DE 68925935 D1 DE68925935 D1 DE 68925935D1 DE 68925935 T DE68925935 T DE 68925935T DE 68925935 T DE68925935 T DE 68925935T DE 68925935 D1 DE68925935 D1 DE 68925935D1
Authority
DE
Germany
Prior art keywords
beta
antibodies against
against interleukin
interleukin
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68925935T
Other languages
English (en)
Other versions
DE68925935T2 (de
Inventor
Setsuyoshi - Uetsuki
Osamu Sato
Yasuo Nakayama
Yoshikatsu Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of DE68925935D1 publication Critical patent/DE68925935D1/de
Application granted granted Critical
Publication of DE68925935T2 publication Critical patent/DE68925935T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE68925935T 1988-10-01 1989-09-28 Antikörper gegen Interleukin-1-beta Expired - Fee Related DE68925935T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24853588 1988-10-01

Publications (2)

Publication Number Publication Date
DE68925935D1 true DE68925935D1 (de) 1996-04-18
DE68925935T2 DE68925935T2 (de) 1996-08-14

Family

ID=17179630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68925935T Expired - Fee Related DE68925935T2 (de) 1988-10-01 1989-09-28 Antikörper gegen Interleukin-1-beta

Country Status (3)

Country Link
US (1) US5348858A (de)
EP (1) EP0364778B1 (de)
DE (1) DE68925935T2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229252T2 (de) * 1991-08-16 1999-12-16 Merck & Co Inc DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (de) * 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
ES2569917T3 (es) 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
JP5607613B2 (ja) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 関節リウマチの治療のための方法
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
MX337586B (es) 2010-05-07 2016-03-11 Xoma Us Llc Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954A1 (de) 2018-08-13 2021-06-23 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
ZA872784B (en) * 1986-05-01 1987-10-16 Immunex Corporation Detection of inflammation and novel antibodies therefor
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1

Also Published As

Publication number Publication date
US5348858A (en) 1994-09-20
EP0364778A1 (de) 1990-04-25
EP0364778B1 (de) 1996-03-13
DE68925935T2 (de) 1996-08-14

Similar Documents

Publication Publication Date Title
DE68925935D1 (de) Antikörper gegen Interleukin-1-beta
DE3785994T2 (de) Antikörper gegen Interleukin-1.
ES2012750A4 (es) Conjunto recipiente-aplicador
BR8902517A (pt) Ampola
ATA900689A (de) Calcitoninpeptide
DK348289D0 (da) Forbindelser
ATA172889A (de) Furanderivate
NO894790D0 (no) Beta-aminoboronsyrederivater.
FI905812A0 (fi) Interleukin-1 inhibitorer.
DK532589D0 (da) Referenceelektrode
DK657089D0 (da) Thiourinstofderivater
ATA205688A (de) Tube
DK466689A (da) Leukotrien-antagonistforlaegemidler
DE68910819T2 (de) Entladungsgerät.
KR900700455A (ko) 치료제
KR900006336U (ko) 튜브
ATA296888A (de) Labyrinthanordnung
KR890022746U (ko) 수치가 표시된 집게
FI911543A0 (fi) Low-loss ytvaogsfilter med belastad kopplingskonverter.
IT8802114A0 (it) Vs1c interfaccia
KR890016935U (ko) 포서기
KR900009566U (ko) 반 합
IT216207Z2 (it) Taglia tigella
IT8840029A0 (it) Equalizzatore
BR8800915A (pt) Policleta

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee